PSTV Cytori Therapeutics Company Cash on Hand

Official company branding of Plus Therapeutics (PSTV)

Plus Therapeutics, Inc. (PSTV) faces risks due to a lack of consistent revenue resulting from a high dependency on the early stages of radiopharmaceutical development. Cash and cash equivalents demonstrate financial stability, with the parameter reaching 0.01. The business model relies on outsourcing production and testing to minimize capital expenditures. Plus Therapeutics, Inc. (PSTV) develops targeted isotopic agents for neuro-oncologists, targeting the nuclear medicine market.

Plus Therapeutics, Inc. - PSTV Company Total Cash Amount (period 07/04/2022 - 08/03/2026)

Summary analytical data breakdowns for plustherapeutics.com (PSTV)

- stock value and consensus price forecast:
Fundamental valuation:Plus Therapeutics Inc
Brand item of Plus Therapeutics, Inc.

This indicator measures liquid capital to assess the business's capacity for autonomous development without external borrowing. By analyzing cash resources totaling 0.01, an investor can diagnose the risk of funding shortages; for Plus Therapeutics, Inc. (PSTV), this is critical, as uncertainty regarding clinical data for radiopharmaceuticals forces the company to cover cash flow gaps through dilutive secondary offerings.